Sonnet BioTherapeutics Shares Jump After Janssen Pact For Its Three Product Candidates

Benzinga · 10/31/2022 14:57
  • Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) announced a collaboration agreement with Janssen Biotech Inc, a Johnson & Johnson (NYSE:JNJ) unit.
  • In vitro and in vivo efficacy of SON-1010 (IL12-FHAB), SON-1210 (IL12-FHAB-IL15), and SON-1410 (IL18-FHAB-IL12) will be evaluated in combination with certain Janssen proprietary cell therapy assets. 
  • The agreement was facilitated by Johnson & Johnson Innovation.
  • Sonnet shall supply the three referenced compounds for use in head-to-head studies. If successful and subject to provisions of the agreement, Sonnet could seek an expanded collaboration.
  • "This is Sonnet's first head-to-head evaluation of three FHAB-based drug candidates, the results of which will be instructive for expanded oncology indications. A successful evaluation could lead to a potential license agreement", said Pankaj Mohan, Sonnet's Founder and CEO.
  • In September, Sonnet BioTherapeutics said that SB101 and SB102 studies dosed 19 subjects to date, with the early review of safety setting the stage for further dose escalation.
  • Additional safety and cytokine-specific data are expected during the Q4 of 2022.
  • Price Action: SONN shares are up 64.70% at $1.91 on the last check Monday.